A Phase II Trial of Bevacizumab + Cetuximab + Cisplatin with Concurrent Intensity Modulated Radiation Therapy (IMRT) for Patients with Stage III/IVB Head and Neck Squamous Cell Carcinoma (HNSCC)

BACKGROUND: To evaluate the efficacy and tolerability of the addition of two monoclonal antibodies, bevacizumab and cetuximab, to two cycles of high-dose cisplatin administered concurrently with IMRT for HNSCC. METHODS: Patients with newly diagnosed stage III/IVB (M0) HNSCC received cetuximab (400 m...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Head Neck
Main Authors: Fury, Matthew G., Xiao, Han, Sherman, Eric J., Baxi, Shrujal, Smith-Marrone, Stephanie, Schupak, Karen, Gewanter, Richard, Gelblum, Daphna, Haque, Sofia, Schoder, Heiko, Shah, Jatin P., Katabi, Nora, Kurtzman, Rachel, Lipson, Brynna, Cox, Lisa, Lee, Nancy Y., Pfister, David G.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5398410/
https://ncbi.nlm.nih.gov/pubmed/25784616
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hed.24041
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados